Phio Pharmaceuticals Corp., of Marlborough, Mass., said it entered a research collaboration with the Helmholtz Zentrum München that covers the design and development of new targets based on the company's self-delivering RNAi platform for use in cancer immunotherapies. Read More
Deciphera Pharmaceuticals Inc., of Waltham, Mass., said it priced its registered underwritten public offering of 10.81 million shares of its common stock at $37 each. The gross proceeds are expected to be $400 million, with the underwriters being granted a 30-day option to purchase up to 1.62 million additional shares. Read More
The as-much-as-$15 million follow-on public offering proposed by Honolulu-based Cardax Inc. won't move the company off the island but it's designed to move it from the OCTQB to Nasdaq. Read More
Birth defects in mitochondrial genes can lead to devastating pediatric disorders with death within a year of birth, and when the dysfunction is milder it can lead to various types of degenerative conditions, including neurodegeneration. Read More
Companies developing RNA-based therapies are now attracting significant investments, and the technologies and emerging products in the field have become desirable assets for big biopharmaceutical companies. In fact, during the past two years 20 deals have been executed, according to BioWorld data. Read More
Congress may be on its August recess, but that doesn't mean lawmakers seeking re-election next year and presidential contenders are taking a break from their campaign against U.S. prescription drug prices. Read More
The FDA cleared Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small-cell lung cancer, also granting accelerated approval to the tyrosine kinase inhibitor for adult and pediatric patients (12 and older) with solid tumors that have a NTRK gene fusion. Read More
Three years after its European approval, U.S. clearance for the narcolepsy drug Wakix (pitolisant) has arrived. Privately held Harmony Biosciences LLC will market the once-daily medicine, licensed from Bioprojet Societe Civile de Recherche, for the treatment of excessive daytime sleepiness (EDS) in adults with the chronic sleep disorder. Read More
Although two heavy hitters' drugs have been approved in the marginal zone lymphoma (MZL) setting where New York-based TG Therapeutics Inc. is due to report important data during the fourth quarter, the company just might have an edge with its oral PI3K-delta inhibitor, umbralisib. Read More
We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More
